Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone

A. Pilkova, M. Sima, JM. Hartinger, TMP. Nikrynova Nguyen, V. Maresova, I. Kurcova, O. Slanar, J. Widimsky

. 2024 ; 168 (2) : 117-123. [pub] 20221202

Language English Country Czech Republic

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24011934

AIM: The aim of this study was to evaluate adherence to spironolactone in a group of unselected patients with arterial hypertension by analysis of measured serum spironolactone and canrenone concentrations according to a proposed two-step decision scheme based on pharmacokinetic considerations. MATERIALS AND METHODS: Simulation of serum concentration-time profiles of spironolactone and canrenone based on population pharmacokinetic parameters described in literature and a body weight-normalized spironolactone dose / canrenone level nomogram derived from a group of adherent patients with conservatively treated primary hyperaldosteronism, were used to create a two-step decision scheme. 71 outpatients treated with spironolactone for resistant hypertension with spironolactone and canrenone serum concentrations measured between 2018 and 2021 were analyzed according to the proposed scheme. We compared our proposed methodology to the standard approach for adherence testing. RESULTS: With the most sensitive traditional approach to adherence assessment through detectable serum concentrations of spironolactone and/or canrenone, 9 (12.7%) non-adherent patients were identified. With our two-step assessment of adherence, we were able to identify 18 (25.4%) non-adherent patients. CONCLUSION: Consideration of the pharmacokinetic properties of parental drug and its metabolite led to improved sensitivity in non-adherence detection in patients with arterial hypertension. This approach enables better interpretation of measured spironolactone and canrenone serum concentrations and should be used in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24011934
003      
CZ-PrNML
005      
20250507135909.0
007      
ta
008      
240711s2024 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2022.048 $2 doi
035    __
$a (PubMed)36472169
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Pilková, Alena $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0244562
245    10
$a Novel approach to adherence assessment based on parent drug and metabolite pharmacokinetics: pilot study with spironolactone / $c A. Pilkova, M. Sima, JM. Hartinger, TMP. Nikrynova Nguyen, V. Maresova, I. Kurcova, O. Slanar, J. Widimsky
520    9_
$a AIM: The aim of this study was to evaluate adherence to spironolactone in a group of unselected patients with arterial hypertension by analysis of measured serum spironolactone and canrenone concentrations according to a proposed two-step decision scheme based on pharmacokinetic considerations. MATERIALS AND METHODS: Simulation of serum concentration-time profiles of spironolactone and canrenone based on population pharmacokinetic parameters described in literature and a body weight-normalized spironolactone dose / canrenone level nomogram derived from a group of adherent patients with conservatively treated primary hyperaldosteronism, were used to create a two-step decision scheme. 71 outpatients treated with spironolactone for resistant hypertension with spironolactone and canrenone serum concentrations measured between 2018 and 2021 were analyzed according to the proposed scheme. We compared our proposed methodology to the standard approach for adherence testing. RESULTS: With the most sensitive traditional approach to adherence assessment through detectable serum concentrations of spironolactone and/or canrenone, 9 (12.7%) non-adherent patients were identified. With our two-step assessment of adherence, we were able to identify 18 (25.4%) non-adherent patients. CONCLUSION: Consideration of the pharmacokinetic properties of parental drug and its metabolite led to improved sensitivity in non-adherence detection in patients with arterial hypertension. This approach enables better interpretation of measured spironolactone and canrenone serum concentrations and should be used in clinical practice.
650    _2
$a lidé $7 D006801
650    12
$a spironolakton $x farmakokinetika $7 D013148
650    _2
$a pilotní projekty $7 D010865
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a kanrenon $x farmakokinetika $7 D002192
650    _2
$a lidé středního věku $7 D008875
650    12
$a adherence k farmakoterapii $7 D055118
650    12
$a hypertenze $x farmakoterapie $7 D006973
650    _2
$a senioři $7 D000368
650    _2
$a antagonisté mineralokortikoidních receptorů $x farmakokinetika $7 D000451
650    _2
$a dospělí $7 D000328
650    _2
$a hyperaldosteronismus $x farmakoterapie $x krev $7 D006929
655    _2
$a časopisecké články $7 D016428
700    1_
$a Šíma, Martin $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0222901
700    1_
$a Hartinger, Jan $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0224709
700    1_
$a Nikrýnová Nguyen, Thi Minh Phuong $u Third Internal Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 _AN114348
700    1_
$a Marešová, Věra, $d 1955- $u Institute of Forensic Medicine and Toxicology, Toxicology Laboratory, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 jo2003163134
700    1_
$a Kurcová, Ivana $u Institute of Forensic Medicine and Toxicology, Toxicology Laboratory, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0108673
700    1_
$a Slanař, Ondřej $u Department of Clinical Pharmacology and Pharmacy, Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0058262
700    1_
$a Widimský, Jiří, $d 1956- $u Third Internal Department of Endocrinology and Metabolism, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 jn99240001422
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 2 (2024), s. 117-123
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36472169 $y Pubmed
910    __
$a ABA008 $b A 1502 $c 958 $y p $z 0
990    __
$a 20240711 $b ABA008
991    __
$a 20250507135906 $b ABA008
999    __
$a ok $b bmc $g 2316447 $s 1223786
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 168 $c 2 $d 117-123 $e 20221202 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
LZP    __
$b NLK124 $a Pubmed-20240711

Find record

Citation metrics

Archiving options